Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)-Reference-Cited by-同舟云学术

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

Published:2011-10-14 Issue:1 Volume:11 Page:
ISSN:1471-244X
Container-title:BMC Psychiatry
language:en
Short-container-title:BMC Psychiatry

Author:

Crivera Concetta,DeSouza Cherilyn,Kozma Chris M,Dirani Riad D,Mao Lian,Macfadden Wayne

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health

Link

http://link.springer.com/content/pdf/10.1186/1471-244X-11-168.pdf

Reference20 articles.

1. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J: The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005, 66: 1122-1129. 10.4088/JCP.v66n0906.

2. Wyatt RJ, Henter I, Leary MC, Taylor E: An economic evaluation of schizophrenia--1991. Soc Psychiatry Psychiatr Epidemiol. 1995, 30 (5): 196-205.

3. Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, Yook KH: Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry. 2008, 32 (5): 1231-1235. 10.1016/j.pnpbp.2008.03.012.

4. Sun SX, Liu GG, Christensen DB, Fu AZ: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007, 23 (10): 2305-2312. 10.1185/030079907X226050.

5. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003, 160 (6): 1125-1132. 10.1176/appi.ajp.160.6.1125.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients;Clinical Drug Investigation;2024-02-22

2. Correlates of unscheduled and emergency clinical contact in a cohort of patients treated for psychosis;Psychiatry Research Communications;2022-03

3. Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta‐analysis of observational studies;Pharmacology Research & Perspectives;2022-01-28

4. Cost of Illness Trends of Schizophrenia from 2010 to 2022: A Systematic Review;J PHARM NEGAT RESULT;2022

5. Correlates of preferring a passive role in decision-making among patients with schizophrenia or bipolar disorder;Patient Education and Counseling;2021-05